Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 26.80 |
| Open | 26.38 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 26.38 - 26.60 |
| 52-week range | 26.03 - 39.90 |
| Volume | |
| Avg. volume | 23,517 |
| Market cap | 41.216B |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | 25.29 |
| EPS (TTM) | 1.05 |
| Earnings date | N/A |
| Forward dividend & yield | 1.66 (4.97%) |
| Ex-dividend date | 29 Sept 2021 |
| 1y target est | N/A |
- Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
CAMBRIDGE, Mass., December 02, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the United States commercial availability of LIVTENCITY™ (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
- Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy as a Hedge Against Inflation
Icahn Enterprises and Takeda Pharmaceutical are two intriguing hedges against sky-high inflation rates.
- Business Wire
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
CAMBRIDGE, Mass., November 30, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program gra
